Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPDD 00031705
Description: Negative control for PDD 00017238 (Cat. No. 7007)
Chemical Name: 1-[(2,4-Dimethyl-5-thiazolyl)methyl]-2,3-dihydro-N-methyl-N-(1-methylcyclopropyl)-2-oxo-3-(1,2,4-thiadiazol-5-yl)-1H-benzimidazole-5-sulfonamide
Purity: ≥98% (HPLC)
Biological Activity for PDD 00031705
PDD 00031705 is a negative control for PDD 00017238 (Cat. No. 7007).
Technical Data for PDD 00031705
| M. Wt | 490.62 |
| Formula | C20H22N6O3S3 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 2032096-45-8 |
| PubChem ID | 123131658 |
| InChI Key | KWGUETFSHQZXMA-UHFFFAOYSA-N |
| Smiles | CN(S(=O)(C1=CC=C2N(C(N(C2=C1)C3=NC=NS3)=O)CC4=C(N=C(S4)C)C)=O)C5(CC5)C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for PDD 00031705
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 4.91 | 10 |
Preparing Stock Solutions for PDD 00031705
The following data is based on the product molecular weight 490.62. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 20.38 mL | 101.91 mL | 203.82 mL |
| 0.5 mM | 4.08 mL | 20.38 mL | 40.76 mL |
| 1 mM | 2.04 mL | 10.19 mL | 20.38 mL |
| 5 mM | 0.41 mL | 2.04 mL | 4.08 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for PDD 00031705
References for PDD 00031705
References are publications that support the biological activity of the product.
James et al (2016) First-in-class chemical probes against poly(ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to Olaparib. ACS Chem.Biol. 11 3179 PMID: 27689388
If you know of a relevant reference for PDD 00031705, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: PDD 00031705, PDD 00031705 supplier, PDD00031705, poly, ADP, ribose, glycohydrolase, PARG, inhibitors, negative, controls, Poly(ADP)-ribose, Glycohydrolase, 7009, Tocris Bioscience
1 Citation for PDD 00031705
Citations are publications that use Tocris products. Selected citations for PDD 00031705 include:
Craig A et al (2018) Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci Rep 8 2709 PMID: 29426911
Do you know of a great paper that uses PDD 00031705 from Tocris? Please let us know.
Reviews for PDD 00031705
There are currently no reviews for this product. Be the first to review PDD 00031705 and earn rewards!
Have you used PDD 00031705?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Epigenetics in Cancer PosterUpdated
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.